Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Bivalent oral cholera vaccine in participants aged 1 year and older in the Dominican Republic: A phase III, single-arm, safety and immunogenicity trial.

Cordero De Los Santos L, Feris-Iglesias J, Aloysia D'Cor N, Midde VJ, Patnaik BN, Thollot Y, Rasuli A, Desauziers E.

Hum Vaccin Immunother. 2018 Jun 3;14(6):1403-1411. doi: 10.1080/21645515.2018.1430540. Epub 2018 Feb 22.

2.

Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines.

Capeding MRZ, Gonzales MLAM, Dhingra MS, D'Cor NA, Midde VJ, Patnaik BN, Thollot Y, Desauziers E.

Hum Vaccin Immunother. 2017 Oct 3;13(10):2232-2239. doi: 10.1080/21645515.2017.1342908.

3.

A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.

Russo P, Ligsay AD, Olveda R, Choi SK, Kim DR, Park JY, Park JY, Syed KA, Dey A, Kim YH, Lee SH, Kim J, Chon Y, Digilio L, Kim CW, Excler JL.

Vaccine. 2018 Jul 5;36(29):4317-4324. doi: 10.1016/j.vaccine.2018.05.102. Epub 2018 Jun 9.

4.

Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age.

Saha A, Chowdhury MI, Khanam F, Bhuiyan MS, Chowdhury F, Khan AI, Khan IA, Clemens J, Ali M, Cravioto A, Qadri F.

Vaccine. 2011 Oct 26;29(46):8285-92. doi: 10.1016/j.vaccine.2011.08.108. Epub 2011 Sep 9.

PMID:
21907255
5.

Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti.

Charles RC, Hilaire IJ, Mayo-Smith LM, Teng JE, Jerome JG, Franke MF, Saha A, Yu Y, Kováč P, Calderwood SB, Ryan ET, LaRocque RC, Almazor CP, Qadri F, Ivers LC, Harris JB.

PLoS Negl Trop Dis. 2014 May 1;8(5):e2828. doi: 10.1371/journal.pntd.0002828. eCollection 2014 May.

6.

Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea.

Baik YO, Choi SK, Kim JW, Yang JS, Kim IY, Kim CW, Hong JH.

J Korean Med Sci. 2014 Apr;29(4):494-501. doi: 10.3346/jkms.2014.29.4.494. Epub 2014 Apr 1. Erratum in: J Korean Med Sci. 2014 Aug;29(8):1182.

7.

Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.

Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA.

Bull Pan Am Health Organ. 1995 Dec;29(4):312-21.

PMID:
8605522
8.

Vibriocidal antibody responses to a bivalent killed whole-cell oral cholera vaccine in a phase III trial in Kolkata, India.

Kanungo S, Lopez AL, Ali M, Manna B, Kim DR, Mahapatra T, Holmgren J, Dhingra MS, Weirzba TF, Nair GB, Bhattacharya SK, Clemens JD, Sur D.

PLoS One. 2014 May 6;9(5):e96499. doi: 10.1371/journal.pone.0096499. eCollection 2014.

9.

A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines.

Baik YO, Choi SK, Olveda RM, Espos RA, Ligsay AD, Montellano MB, Yeam JS, Yang JS, Park JY, Kim DR, Desai SN, Singh AP, Kim IY, Kim CW, Park SN.

Vaccine. 2015 Nov 17;33(46):6360-5. doi: 10.1016/j.vaccine.2015.08.075. Epub 2015 Sep 5.

PMID:
26348402
10.

Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45.

McCarty JM, Lock MD, Hunt KM, Simon JK, Gurwith M.

Vaccine. 2018 Feb 1;36(6):833-840. doi: 10.1016/j.vaccine.2017.12.062. Epub 2018 Jan 6.

11.

Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam.

Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, Hung NV, Canh DG, Thiem VD, Naficy A, Ivanoff B, Svennerholm AM, Holmgren J, Clemens JD.

Bull World Health Organ. 2002;80(1):2-8.

12.

The oral cholera vaccine Shanchol™ when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants.

Saha A, Khan A, Salma U, Jahan N, Bhuiyan TR, Chowdhury F, Khan AI, Khanam F, Muruganandham S, Reddy Kandukuri S, Singh Dhingra M, Clemens JD, Cravioto A, Qadri F.

Vaccine. 2016 Mar 18;34(13):1551-1558. doi: 10.1016/j.vaccine.2016.02.020. Epub 2016 Feb 16.

PMID:
26896684
13.

Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone.

Kanungo S, Desai SN, Nandy RK, Bhattacharya MK, Kim DR, Sinha A, Mahapatra T, Yang JS, Lopez AL, Manna B, Bannerjee B, Ali M, Dhingra MS, Chandra AM, Clemens JD, Sur D, Wierzba TF.

PLoS Negl Trop Dis. 2015 Mar 12;9(3):e0003574. doi: 10.1371/journal.pntd.0003574. eCollection 2015 Mar.

14.

Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.

Shamsuzzaman S, Ahmed T, Mannoor K, Begum YA, Bardhan PK, Sack RB, Sack DA, Svennerholm AM, Holmgren J, Qadri F.

Vaccine. 2009 Feb 25;27(9):1386-92. doi: 10.1016/j.vaccine.2008.12.041. Epub 2009 Jan 13.

PMID:
19146897
15.

A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.

Desai SN, Akalu Z, Teshome S, Teferi M, Yamuah L, Kim DR, Yang JS, Hussein J, Park JY, Jang MS, Mesganaw C, Taye H, Beyene D, Bedru A, Singh AP, Wierzba TF, Aseffa A.

Am J Trop Med Hyg. 2015 Sep;93(3):527-33. doi: 10.4269/ajtmh.14-0683. Epub 2015 Jun 15.

16.

An Open Label Non-inferiority Trial Assessing Vibriocidal Response of a Killed Bivalent Oral Cholera Vaccine Regimen following a Five Year Interval in Kolkata, India.

Kanungo S, Desai SN, Saha J, Nandy RK, Sinha A, Kim DR, Bannerjee B, Manna B, Yang JS, Ali M, Sur D, Wierzba TF.

PLoS Negl Trop Dis. 2015 May 29;9(5):e0003809. doi: 10.1371/journal.pntd.0003809. eCollection 2015 May.

17.

Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers.

Islam K, Hossain M, Kelly M, Mayo Smith LM, Charles RC, Bhuiyan TR, Kováč P, Xu P, LaRocque RC, Calderwood SB, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Kirkpatrick BD, Cohen M, Levine MM, Gurwith M, Harris JB, Qadri F, Ryan ET.

PLoS Negl Trop Dis. 2018 Apr 6;12(4):e0006376. doi: 10.1371/journal.pntd.0006376. eCollection 2018 Apr.

18.
19.

Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru.

Taylor DN, Tacket CO, Losonsky G, Castro O, Gutierrez J, Meza R, Nataro JP, Kaper JB, Wasserman SS, Edelman R, Levine MM, Cryz SJ.

Infect Immun. 1997 Sep;65(9):3852-6.

20.

A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India.

Mahalanabis D, Lopez AL, Sur D, Deen J, Manna B, Kanungo S, von Seidlein L, Carbis R, Han SH, Shin SH, Attridge S, Rao R, Holmgren J, Clemens J, Bhattacharya SK.

PLoS One. 2008 Jun 4;3(6):e2323. doi: 10.1371/journal.pone.0002323.

Supplemental Content

Support Center